Literature DB >> 12422907

Antibiotic administration in patients with preterm premature rupture of membranes reduces the rate of histological chorioamnionitis: a prospective, randomized, controlled study.

A Ovalle1, M A Martínez, E Kakarieka, R Gómez, R Rubio, O Valderrama, H Leyton.   

Abstract

OBJECTIVE: To determine whether antibiotic administration in patients with preterm premature rupture of membranes is associated with a reduction in the rate of histological chorioamnionitis and funisitis.
METHODS: One hundred consecutive patients with preterm premature rupture of membranes and no labor between 24 and 34 weeks were invited to participate in this study. Eligible patients randomly received either clindamycin-gentamicin for 7 days or placebo, and were managed expectantly until 35 weeks unless fetal or maternal indications developed. Microbial invasion of the amniotic cavity was defined as the presence of a positive amniotic fluid culture obtained by transabdominal amniocentesis. Cervicovaginal infection was diagnosed when bacterial vaginosis or a positive culture for cervicovaginal pathogens or facultative bacteria associated with a significant increase in the white blood cell count were found. Histological chorioamnionitis was based on the observation of polymorphonuclear leukocyte infiltration of the chorionic plate or the extraplacental fetal membranes. Funisitis was diagnosed in the presence of polymorphonuclear leukocyte infiltration into the umbilical vessel walls or Wharton jelly. Statistics were performed using contingency tables.
RESULTS: Seventy-one patients with available histological study of the placenta were included. Thirty-five women received antibiotics and 36 were given placebo. Patients who received antibiotics had a significantly lower rate of histological chorioamnionitis than patients who received placebo (46% (16/35) vs. 69% (25/36), respectively; p < 0.05). This effect was more pronounced among women with microbial invasion of the amniotic cavity and/or cervicovaginal infection (58% vs. 89%, respectively; p < 0.01). Antibiotic therapy was associated with an increase in the frequency of placentas without histological abnormalities (29% vs. 6%; p < 0.01). The frequency of funisitis was not different between groups.
CONCLUSION: Administration of antibiotics in patients with preterm premature rupture of membranes is associated with a significant reduction in the incidence of histological chorioamnionitis but it does not modify the frequency of funisitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12422907     DOI: 10.1080/jmf.12.1.35.41

Source DB:  PubMed          Journal:  J Matern Fetal Neonatal Med        ISSN: 1476-4954


  5 in total

1.  Vaginal and oral microbes, host genotype and preterm birth.

Authors:  Usha Srinivasan; Dawn Misra; Mary L Marazita; Betsy Foxman
Journal:  Med Hypotheses       Date:  2009-12       Impact factor: 1.538

2.  Sterile and microbial-associated intra-amniotic inflammation in preterm prelabor rupture of membranes.

Authors:  Roberto Romero; Jezid Miranda; Piya Chaemsaithong; Tinnakorn Chaiworapongsa; Juan P Kusanovic; Zhong Dong; Ahmed I Ahmed; Majid Shaman; Kia Lannaman; Bo Hyun Yoon; Sonia S Hassan; Chong Jai Kim; Steven Jai Korzeniewski; Lami Yeo; Yeon Mee Kim
Journal:  J Matern Fetal Neonatal Med       Date:  2014-09-29

3.  The Effect of Non-penicillin Antibiotic Regimens on Neonatal Outcomes in Preterm Premature Rupture of Membranes.

Authors:  Anne M Siegel; Robert Phillips Heine; Sarah K Dotters-Katz
Journal:  AJP Rep       Date:  2019-03-07

4.  Developing a Core Outcome Set for the Evaluation of Antibiotic Use in Prelabor Rupture of Membranes: A Systematic Review and Semi-Structured Interview.

Authors:  Dan Liu; Lin Wu; Jiefeng Luo; Siyu Li; Yan Liu; Chuan Zhang; Linan Zeng; Qin Yu; Lingli Zhang
Journal:  Front Pharmacol       Date:  2022-08-01       Impact factor: 5.988

5.  Non-Invasive Prediction of Histologic Chorioamnionitis in Women with Preterm Premature Rupture of Membranes.

Authors:  Su Ah Kim; Kyo Hoon Park; Seung Mi Lee
Journal:  Yonsei Med J       Date:  2016-03       Impact factor: 2.759

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.